Illustrative image.
Kanjinti
Trastuzumab
$1800.00
420mg · 1 vial
BrandBranded medicine· By Amgen
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningCardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity
Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue KANJINTI for cardiomyopathy.
Infusion Reactions, Pulmonary Toxicity: Discontinue KANJINTI for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception.
About Kanjinti
Overview
Kanjinti (trastuzumab-anns) is a monoclonal antibody medicine given into a vein. It is used in adults to treat breast cancer and metastatic stomach or gastroesophageal junction adenocarcinoma that overexpress HER2, meaning the cancer cells have high levels of this protein. Testing is used to select patients for treatment. It binds to HER2 on cancer cells, helping to slow their growth and support immune cells in attacking them.
What it treats
- HER2-overexpressing breast cancer in adults. - HER2-overexpressing metastatic adenocarcinoma of the stomach or gastroesophageal junction in adults. Treatment eligibility is based on an FDA-approved companion diagnostic test for a trastuzumab product.
Safety information
Side effects
Common side effects vary by the cancer being treated. In adjuvant breast cancer treatment, they include headache, diarrhea, nausea and chills. In metastatic breast cancer treatment, they include fever, chills, headache, infection, difficulty sleeping, cough and rash. In metastatic gastric cancer treatment, they include low white blood cell counts, diarrhea, tiredness, anemia, mouth sores, weight loss, upper respiratory tract infections, fever, low platelet counts, inflammation of moist body linings, nose and throat inflammation, and changes in taste. Serious side effects that warrant contacting a doctor include heart muscle damage and congestive heart failure, infusion reactions, lung toxicity, and worsening of chemotherapy-related low white blood cell counts. Congestive heart failure is also listed among the most common side effects in metastatic breast cancer treatment. Kanjinti can harm an unborn baby; contact your doctor if you become pregnant during treatment.
FDA boxed warning
Cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity
Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue KANJINTI for cardiomyopathy.
Infusion Reactions, Pulmonary Toxicity: Discontinue KANJINTI for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The label lists no contraindications for Kanjinti. Caution is needed because it may worsen chemotherapy-induced neutropenia (a low level of certain white blood cells). Pregnancy status should be checked before treatment starts in patients who could become pregnant.
Using Kanjinti
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label KANJINTI (TRASTUZUMAB-ANNS) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [AMGEN, INC] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Trazimera
Trastuzumab
By Pfizer
Pack · from 1 per pack
Same active ingredient as Kanjinti
Brand $1,800.00
Herceptin Hylecta
Trastuzumab
By Roche
Vial · from 1 per pack
Same active ingredient as Kanjinti
Brand from $1,740.00
HERZUMA
Trastuzumab
By Celltrion
Vial · from 1 per pack
Same active ingredient as Kanjinti
Brand $1,800.00
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00